PF 3185043
Alternative Names: PF-3185043Latest Information Update: 21 Apr 2009
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antihyperlipidaemics; Cardiovascular therapies
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 20 Dec 2006 Phase-I clinical trials in Atherosclerosis in USA (unspecified route)